Blood Cancer Journal - Table of Contents alert Volume 4 September 2014

If you are unable to see the message below, click here to view.

Advertisement BD FACSCantoTM has 10-color capability. Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences.  bdbiosciences.com/go/canto   TABLE OF CONTENTS Volume 4, September 2014 In this issue Letter to the Editor Corrigendum Sign up for e-alerts Web feed Advertisement Blood Cancer Journal: submit your next manuscript Blood Cancer Journal is an open access journal, publishing research and review articles of the highest quality on hematologic malignancies and related disorders, and recently received a first Impact Factor of 2.884*. Discover the benefits of publishing with Blood Cancer Journal. *2013 Journal Citation Reports® Science Edition (Thomson Reuters, 2014)   Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion A Maurizot, J-P Beressi, B Manéglier, N H de la Marre, M Spentchian, P Soury, P Solvet-Sebire, C Collet-Gaudillat, J-M Baud, B Livarek, F Guilhot and P Rousselot Blood Cancer J 2014 4: e247; 10.1038/bcj.2014.66 Full Text Monthly administration of rituximab is useful for patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma T Mino, K Mihara, T Yoshida, Y Takihara and T Ichinohe Blood Cancer J 2014 4: e245; 10.1038/bcj.2014.65 Full Text Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia G Zugmaier, M S Topp, S Alekar, A Viardot, H-A Horst, S Neumann, M Stelljes, R C Bargou, M Goebeler, D Wessiepe, E Degenhard, N Gökbuget and M Klinger Blood Cancer J 2014 4: 244; 10.1038/bcj.2014.64 Full Text Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia K D Cummins, S M Jane, S Ninkovic, A Bazargan, R Filshie, G Sutrave, M Hertzberg, A Scott, S Lane, C K Yannakou, D Ritchie, J D'Rozario, J Black, K Bavishi and A Wei Blood Cancer J 2014 4: e246; 10.1038/bcj.2014.68 Full Text You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.